SPAS(SH:603168) Shang Hai Zheng Quan Bao·2025-10-30 22:47Core Viewpoint - The company has announced significant updates regarding its financial performance, corporate governance, and product approvals, which may impact its market position and investor interest. Financial Performance - The third-quarter financial report for 2025 has been prepared but is not audited [3] - The report includes key financial data and indicators, although specific figures are not disclosed in the provided documents [3][4] Corporate Governance - The company plans to repurchase and cancel 1,798,500 restricted shares due to certain employees leaving and performance not meeting targets, reducing total shares from 375,925,005 to 374,126,505 [7][8] - A board meeting was held on October 30, 2025, where several resolutions were passed, including the approval of the third-quarter report and the election of board members [34][36][41] Shareholder Meeting - The second extraordinary general meeting of shareholders is scheduled for November 19, 2025, with both on-site and online voting options available [10][12] - Shareholders must register to attend the meeting, with specific requirements outlined for both corporate and individual shareholders [20][25] Product Approval - The company received approval for a supplementary application for sodium hyaluronate eye drops, which will enhance its product line and market competitiveness [32][33] - The total R&D investment for this project is approximately 6.5889 million RMB [32]